Fluorine F 18 FEQA in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer and in Healthy Participants

Stopped early · Not applicable

Conditions studied: Lung Cancer

In brief

RATIONALE: Fluorine F 18 FEQA may be an effective radioactive drug to use with positron emission tomography (PET) scans. PURPOSE: This clinical trial is studying the use of fluorine F 18 FEQA in patients with stage III or stage IV non-small cell lung cancer and in healthy participants.

Key facts

Study ID

NCT00444223

Run by

Jonsson Comprehensive Cancer Center

People needed

3

Starts

2004-05-04

Expected to finish

2008-05-15

Last updated by the study team

2020-08-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Must meet 1 of the following criteria:
• Diagnosis of non-small cell lung cancer by CT scan, bone scan, or biopsy
• Stage III or IV disease
• Clinically assessed with
• Healthy participant

Where it is running

• Jonsson Comprehensive Cancer Center at UCLA — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.